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Background: Bronchopulmonary dysplasia (BPD) is a common chronic lung disease associated with very preterm
birth. The major risk factors include lung inflammation and lung immaturity. In addition, genetic factors play an
important role in susceptibility to moderate-to-severe BPD. In this study, the aim was to investigate whether
common polymorphisms of specific genes that are involved in inflammation or differentiation of the lung have
influence on BPD susceptibility.
Methods: Genes encoding interleukin-6 (IL6) and its receptors (IL6R and IL6ST), IL-10 (IL10), tumor necrosis factor
(TNF), and glucocorticoid receptor (NR3C1) were assessed for associations with moderate-to-severe BPD susceptibility.
Five IL6, nine IL6R, four IL6ST, one IL10, two TNF, and 23 NR3C1 single nucleotide polymorphisms (SNPs) were analyzed
in very preterm infants born in northern Finland (56 cases and 197 controls) and Canada (58 cases and 68 controls).
IL-6, TNF and gp130 contents in umbilical cord blood, collected from very preterm infants, were studied for associations
with the polymorphisms. Epistasis (i.e., interactions between SNPs in BPD susceptibility) was also examined. SNPs
showing suggestive associations were analyzed in additional replication populations from Finland (39 cases and 188
controls) and Hungary (29 cases and 40 controls).
Results: None of the studied SNPs were associated with BPD nor were the IL6, TNF or IL6ST SNPs associated with cord
blood IL-6, TNF and gp130, respectively. However, epistasis analysis suggested that SNPs in IL6ST and IL10 were associated
interactively with risk of BPD in the northern Finnish population; however, this finding did not remain significant after
correction for multiple testing and the finding was not replicated in the other populations.
Conclusions: We conclude that the analyzed SNPs within IL6, IL6R, IL6ST, IL10, TNF, and NR3C1 were not associated with
BPD. Furthermore, there was no evidence that the studied SNPs directly contribute to the cord blood protein contents.
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Bronchopulmonary dysplasia (BPD) is a chronic lung
disease that affects infants born very preterm. Despite
advances in treatment practices (including antenatal
glucocorticoid treatment), BPD continues to be a major
cause of neonatal morbidity and mortality in these infants.
Furthermore, infants with BPD are at increased risk of re-
spiratory morbidities in later life, and lung function defects
may persist even into adulthood [1]. Major risk factors
that predispose infants to BPD include prematurity [2],
fetal growth restriction [3], and lung inflammation [4]. In
addition to environmental stressors, the results of twin
studies indicate high heritability for BPD and that the
genetic factors have an important role in predisposition to
BPD [5-7] accounting for up to 79% of the variance in
liability to moderate-to-severe BPD [6]. Despite numerous
candidate gene studies and two genome-wide association
studies, the genetic background of BPD remains incom-
pletely characterized [8-11].
Infants with BPD often have a simplified lung structure.
It has been proposed that initiation of an inflammatory
cascade in immature lung tissue interferes with the normal
course of septation and alveolar development. This leads
to fewer, simplified, and larger alveoli and dysmorphic pul-
monary vasculature, which are typical features of impaired
alveolarization and common findings in BPD [4,12]. In
addition, the inflammatory cytokines are strongly associ-
ated with the airway and interstitial lung injury, and thus,
several inflammatory mediators have been studied for
associations with BPD [13]. Previously, elevated levels of
cytokines were observed in blood, cord blood or amniotic
fluid from infants who subsequently developed BPD
[14-16]. In particular, elevated levels of proinflammatory
cytokine interleukin 6 (IL-6) in blood after birth [14],
glycoprotein 130 (gp130, also known as IL-6 signal trans-
ducer) in cord blood [15] and reduced expression of IL-10
in placenta [17] were associated with risk of BPD.
This case–control study was performed to assess whether
genes involved in inflammation and lung maturation are as-
sociated with susceptibility to moderate-to-severe BPD, de-
fined by the need of supplemental oxygen at the corrected
age of 36 weeks. The genes encoding IL-6 (IL6), its recep-
tors IL-6R (IL6R) and gp130 (IL6ST), IL-10 (IL10), tumor
necrosis factor (TNF) formerly known as TNF-alpha, were
studied. In addition, the gene encoding glucocorticoid re-
ceptor (NR3C1) was selected. Glucocorticoids have strong
anti-inflammatory effects, and they additionally influence
growth and differentiation. The actions of both endogenous
and synthetic glucocorticoids are mediated by the gluco-
corticoid receptor [18,19]. Furthermore, associations be-
tween specific polymorphisms and cord blood serum IL-6,
TNF and gp130 contents were studied. Finally, epistasis was
investigated; i.e., whether interactions between polymor-
phisms in the six analyzed genes affect disease susceptibility.Methods
Written informed consent was obtained from the par-
ents, and the study was approved by the Ethics Commit-
tee of Oulu University Hospital, the University of British
Columbia Clinical Research Ethics Board, the University
of Alberta Ethics Board, and the Semmelweis University
Hospital Ethical Committee.
Diagnosis of BPD and infant inclusion criteria
The diagnosis of BPD was based on a requirement for
supplemental oxygen or ventilation at 36 wk post men-
strual age (PMA). For infants who required supplemen-
tal oxygen for a minimum of 28 d, the severity of BPD
was graded (according to National Institute of Child
Health and Human Development criteria) as mild BPD
(no supplemental O2 requirement or ventilation at 36
wk PMA), moderate BPD (supplemental O2 requirement
<30% at 36 wk PMA), or severe BPD (supplemental O2
requirement ≥30% or ventilation at 36 wk PMA) [20].
The oxygen reduction test [21] was performed for in-
fants born in Finland after 2009; the test eliminated less
than 10% of all cases of moderate BPD. Although infants
from different centers were included in the study, the
possible differences in BPD diagnosis were small since
the transcutaneous oxygen saturation limits were kept
within a close range (lower limit from 86 to 90%; upper
limit from 92 to 95%), the oxygen saturation test was
similar in each center, and of all infants studied only one
third of the Canadian population was treated in moder-
ately high altitude (~670 m).
In case–control analyses, infants with no-to-mild BPD
were controls and infants with moderate-to-severe BPD
were cases. This approach was based on twin studies
that demonstrated significant heritability in moderate-
to-severe BPD but less in mild BPD [6]. We excluded
infants with malformations and those who died before
the diagnosis. Additionally, only one infant was included
from each monozygotic twin pair.
Study populations
All infants were born at gestational age (GA) <31 wk.
Clinical characteristics are presented in Table 1. The
northern Finnish population (n =253) was prospectively
recruited at Oulu University Hospital in 1997–2010.
Only infants with parents of Finnish origin were in-
cluded. The study population that originated Canada
(n =126) comprised infants born in neonatal intensive
care units in Vancouver and Edmonton in 2006–2008, as
described previously [22]. These infants were of European
descent. In addition, two replication populations were
included. The first population comprised infants born
in Finland (n =227) in the university hospitals of Oulu,
Kuopio, Tampere, and Helsinki in 2010–2012 and in
the University Hospital of Turku in 2001–2006 and
Table 1 Clinical characteristics of the northern Finnish, Canadian, replication Finnish, and replication Hungarian
preterm cohorts
Northern Finnish Canadian Replication Finnish Replication Hungarian
BPD cases Controls BPD cases Controls BPD cases Controls BPD cases Controls
n 56 197 58 68 39 188 29 40
Gestational age,
weeks1
27.5 ± 1.9
(24–30)
28.7 ± 1.7
(23–30)***
25.9 ± 1.6
(23–30)
27.6 ± 1.3
(24–30)***
26.5 ± 1.9
(24–30)
27.5 ± 2.0
(23–30)**
26.6 ± 1.8
(24–30)
28.6 ± 1.4 x
24–30)***
Gestational age <28
wk, n (%)
29 (51.8) 64 (32.5)** 48 (82.8) 32 (47.1)*** 30 (76.9) 88 (46.8)** 19 (65.5) 6 (15.0)***
Birth weight, grams1 938 ± 268
(495–1555)
1184 ± 313
(370–1850)***
834 ± 221
(385–1420)
1162 ± 243
(630–1900)***
878 ± 257
(440–1470)
1074 ± 308
(520–1970)***
928 ± 226
(510–1500)
1179 ± 193
(650–1500)***
Birth weight Z-score1,2 −1.4 ± 1.41
(−4.5–1.8)
−0.9 ± 1.22
(−5.5–1.7)*
NA NA −1.4 ± 1.38
(−4.0–1.1)
−0.9 ± 1.3
(−4.0–2.6)
NA NA
IUGR≤ −2 SD, n (%) 21 (37.5) 33 (16.8)** 11 (19.0) 3 (4.4)* 13 (33.3) 41 (21.8) NA NA
Male gender, n (%) 34 (60.7) 111 (56.3) 29 (50.0) 30 (44.1) 26 (66.7) 94 (50.0) 16 (55.2) 24 (60.0)
Singletons, n (%) 47 (83.9) 164 (83.2) 39 (67.2) 44 (64.7) 29 (74.4) 138 (73.4) 26 (89.7) 33 (82.5)
Severe BPD, n (%) 21 (37.5) 21 (36.2) 18 (46.2) NA
*P <0.05, **P <0.01, ***P <0.001; Mann–Whitney U-test for continuous variables, X2-test for dichotomous variables; 1mean ± standard deviation (range); 2Birth weight Z-score
describing fetal intrauterine growth. BPD cases were infants with moderate-to-severe BPD, and controls were infants with no-to-mild BPD. BPD, bronchopulmonary dysplasia;
IUGR, intrauterine growth restriction; NA, information not available.
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ginal analyses because samples were prospectively collected
during or after the original analyses. The second replica-
tion population (n =69) included infants of European des-
cent born in Semmelweis University Hospital, Budapest,
Hungary in 1995–2002.
DNA sample preparation
For the samples collected in Finland, genomic DNA was
extracted from buccal cells, umbilical cord blood, and blood
spots dried on paper with Chelex 100 (Bio-Rad, Hercules,
CA, USA), UltraClean DNA blood Isolation kit (MO BIO
Laboratories Inc., Carlsbad, CA, USA), and MO BIO Ultra-
Clean BloodSpin DNA Isolation Kit (MO BIO Laborator-
ies), respectively. For buccal cell and paper blood DNA
samples, whole-genome amplification was performed, as
described previously [23]. For samples that originated in
Canada, genomic DNA was extracted from umbilical cord
tissue and cell samples, whole blood specimens, and tra-
cheal aspirate samples with the ChargeSwitch gDNA Mini
Tissue Kit (Invitrogen, Carlsbad, CA, USA), QIAamp DNA
Blood Midi Kit (Qiagen, Hilden, Germany), and ChargeS-
witch gDNA Buccal Cell Kit (Invitrogen), respectively.
DNA from the Hungarian samples was extracted from
dried whole blood spots with saponin and Chelex-100, as
described previously [24].
SNP selection and genotyping
Tagging SNPs (tSNPs) that capture most of the common
genetic variation in the selected regions based on linkage
disequilibrium (LD) were selected by using HapMap
data (release 24/phases I&II) [25] for the CEU popula-
tion (CEPH; Utah residents with ancestry from northernand western Europe). A minor allele frequency (MAF)
cut-off value of 0.1 and an r2 cut-off value of 0.9 were
used for pairwise tagging. A total of 44 SNPs (five SNPs
in IL6, nine in IL6R, four in IL6ST, one in IL10, two in
TNF, and 23 in NR3C1) were selected for genotyping.
The analyzed SNPs are listed in Tables 2 and 3.
Genotyping was performed with the Sequenom iPLEX
Gold assay. Three SNPs deviated from Hardy–Weinberg
equilibrium (HWE): IL6R rs4075015 and rs4453032 in the
northern Finnish population and IL6 rs2069840 in the
Canadian population. Because these SNPs deviated from
HWE in only one of the populations, they were included
in analyses. In the replication study, IL6ST rs10471960
and IL10 rs3024493 SNPs were genotyped by PCR-RFLP
analysis with primer pairs of 5′-CAGAGTGGCTTAGG
GACAGTT-3′ (forward) and 5′-ACTCGCAGCATCAC
TACCAAT-3′ (reverse) for rs10471960 and 5′-GGGTG
GCTGCTAGGCATTT-3′ (forward) and 5′-GAATAGC
CCCCTTGTCCCTTC-3′ (reverse) for rs3024493, with
restriction enzymes BssSI and BamHI (New England
Biolabs, Ipswich, MA, USA), respectively.
Analysis of IL-6, TNF and gp130 in umbilical cord blood
specimens
IL-6, TNF and gp130 protein contents were measured from
umbilical cord blood specimens collected from a cohort of
very preterm infants born in Oulu University Hospital dur-
ing 1998–2002, as described previously [15]. A total of 120
infants were included in the analysis: 35 infants subse-
quently developed moderate-to-severe BPD and 85 infants
had no-to-mild BPD. The protocol of the antibody-based
microarray has been previously described in detail [26].
The protein content of blood specimens are reported as
Table 2 IL6, IL6R, IL6ST, IL10, and TNF minor allele frequencies in cases and controls in the northern Finnish and
Canadian populations
Northern Finland, n =253 Canada, n =126
Gene Polymorphism1 Case, control minor allele frequency P value Case, control minor allele frequency P value
IL6 rs2069827 0.286, 0.265 0.6603 0.129, 0.119 0.8126
IL6 rs1800797 0.438, 0.454 0.7592 0.379, 0.388 0.8872
IL6 rs1800795 0.438, 0.454 0.7523 0.404, 0.404 0.9884
IL6 rs2069832 0.427, 0.457 0.5814 0.397, 0.404 0.8990
IL6 rs2069840 0.222, 0.237 0.7464 0.276, 0.243 0.5480
IL6R rs4845617 0.400, 0.426 0.6304 0.276, 0.390 0.0568
IL6R rs1386821 0.214, 0.203 0.795 0.172, 0.213 0.4144
IL6R rs4075015 0.444, 0.423 0.6859 0.509, 0.462 0.4614
IL6R rs4601580 0.417, 0.460 0.4527 0.491, 0.500 0.8898
IL6R rs4553185 0.368, 0.434 0.2218 0.474, 0.463 0.8627
IL6R rs4453032 0.273, 0.320 0.3479 0.431, 0.449 0.7804
IL6R rs4845374 0.116, 0.121 0.8845 0.103, 0.096 0.8352
IL6R rs4240872 0.389, 0.386 0.9567 0.293, 0.257 0.5259
IL6R rs4072391 0.343, 0.361 0.7265 0.216, 0.184 0.5295
IL6ST rs10471960 0.080, 0.104 0.4582 0.129, 0.125 0.9184
IL6ST rs10940495 0.259, 0.303 0.3717 0.267, 0.239 0.6055
IL6ST rs11739048 0.089, 0.105 0.6247 0.155, 0.140 0.7295
IL6ST rs6875155 0.071, 0.103 0.3233 0.121, 0.125 0.9173
IL10 rs3024493 0.120, 0.153 0.3908 0.121, 0.191 0.1270
TNF rs1799964 0.136, 0.155 0.6362 0.198, 0.169 0.5503
TNF rs1800629 0.100, 0.144 0.2359 0.190, 0.132 0.2147
1SNP accession numbers in dbSNP database (http://www.ncbi.nlm.nih.gov/SNP).
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tween cord blood proteins IL-6, TNF and gp130 and SNPs
of the encoding genes was studied; including 100 infants
with DNA sample available.
Statistical analyses
Case–control comparisons for the continuous and dichot-
omous clinical characteristics (GA, birth weight, intrauter-
ine growth expressed as Z-score, intrauterine growth
restriction [IUGR] ≤ −2 SD, gender, and proportion of sin-
gletons) as well as the cord blood IL-6, TNF and soluble
gp130 contents were performed by the nonparametric
Mann–Whitney U-test and the Pearson X2 test with SPSS
Statistics 20.0 (IBM Corporation, Armonk, New York,
USA). Differences in the cord blood IL-6, TNF and gp130
contents among the genotypes were analyzed with Mann–
Whitney U-test and Kruskal–Wallis test. Haploview ver-
sion 4.2 [27] was used for comparing case–control allele
and haplotype frequencies (X2 tests), testing for HWE, and
obtaining pairwise LD values (D′ and r2, where D′ refers
to the strength of LD and r2 describes the correlation
coefficient between the two loci; values close to 1 refer
to strong LD or correlation between the two SNPs,respectively). PLINK 1.07 [28] was used for logistic regres-
sion analyses (to take the effect of potential risk factors
into account together with the genetic factors).
Because some of the 44 SNPs included in the study
were in LD with each other and thus not considered in-
dependent markers, SNPSpD [29], a method that takes
LD between SNPs into account, was used to calculate
the effective number of independent SNPs for each of
the six genes. This resulted in a total of 32 independent
SNPs; using the Bonferroni correction for multiple test-
ing, a P value of <0.0016 was considered significant.
Pairwise SNP–SNP interaction analyses were performed
with the epistasis option in PLINK. The software uses logis-
tic regression (for dichotomous phenotype) to provide an
odds ratio (OR) for the interaction of each pair of SNPs by
considering pairwise combinations of all of the SNPs. Re-
dundant SNPs were excluded from the epistasis analysis
based on the LD measurements (strong LD): only one SNP
from each haploblock generated by Haploview was in-
cluded (see Additional file 1). Additionally, SNPs were ex-
cluded if they showed significant deviation from HWE.
With these exclusion criteria, 22 SNPs were included in the
analysis, resulting in 231 pairwise SNP–SNP comparisons.
Table 3 NR3C1 minor allele frequencies in cases and controls in the northern Finnish and Canadian populations
Northern Finland, n =253 Canada, n =126
NR3C1 polymorphism1 Case, control minor allele frequency P value Case, control minor allele frequency P value
rs17287758 0.107, 0.107 0.9869 0.155, 0.154 0.9867
rs17209237 0.264, 0.237 0.5685 0.219, 0.235 0.7640
rs6196 0.200, 0.184 0.7034 0.198, 0.184 0.7709
rs10482689 0.107, 0.105 0.9381 0.155, 0.154 0.9867
rs10482682 0.339, 0.319 0.6811 0.327, 0.347 0.7529
rs6188 0.309, 0.296 0.7897 0.362, 0.353 0.8802
rs10482672 0.128, 0.132 0.9191 0.172, 0.125 0.2892
rs33383 0.460, 0.500 0.4799 0.482, 0.441 0.5248
rs2918417 0.304, 0.293 0.825 0.366, 0.353 0.8301
rs6877893 0.464, 0.482 0.7372 0.466, 0.441 0.6988
rs4912905 0.241, 0.241 0.9992 0.241, 0.213 0.5945
rs2918415 0.196, 0.178 0.6609 0.198, 0.184 0.7709
rs17399352 0.236, 0.218 0.6763 0.172, 0.206 0.5001
rs2963155 0.321, 0.321 0.9854 0.319, 0.272 0.4151
rs9324924 0.373, 0.409 0.4954 0.397, 0.346 0.4034
rs7701443 0.366, 0.359 0.8903 0.353, 0.353 0.9933
rs4244032 0.134, 0.153 0.6201 0.190, 0.169 0.6714
rs4607376 0.500, 0.495 0.9247 0.500, 0.449 0.4146
rs13182800 0.116, 0.147 0.4074 0.190, 0.169 0.6714
rs12054797 0.255, 0.320 0.1888 0.302, 0.294 0.8953
rs4912910 0.382, 0.414 0.5472 0.353, 0.360 0.9100
rs12656106 0.446, 0.407 0.4619 0.431, 0.508 0.2274
rs12655166 0.268, 0.324 0.2641 0.302, 0.294 0.8953
1SNP accession numbers in dbSNP database (http://www.ncbi.nlm.nih.gov/SNP).
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P <0.00022.
Genetic power of the study
The power of the study was estimated by the Genetic
Power Calculator [30] with an additive risk model (the al-
lelic 1 degree of freedom test assuming a causal SNP with
a MAF range of 0.1–0.5 and a BPD prevalence of 0.2).
Our population of very preterm infants, which included
114 cases and 265 controls (the combined northern
Finnish and Canadian population) provided an estimate of
80% power (alpha =0.05) to detect genotypic relative risks
of 1.56–1.7 for risk-allele carrier heterozygotes.
Results
Clinical characteristics of the BPD and control infants
Some of the clinical characteristics, such as GA, birth
weight, and birth weight Z-score (birth weight adjusted
for gestational age), differed significantly between infants
with moderate-to-severe BPD and control infants with
no-to-mild BPD (Table 1). There were no differences be-
tween cases and controls in the number of fetuses perpregnancy or in gender distribution (Table 1). Differ-
ences in the clinical characteristics were taken into ac-
count in the analyses when applicable.
IL6, IL6R, IL6ST, IL10, TNF and NR3C1 polymorphisms and
haplotypes in BPD cases and controls
The allele frequency distribution of the 44 SNPs in BPD
cases and controls was studied. None of the SNPs were as-
sociated with BPD in the northern Finnish or Canadian
populations (Tables 2 and 3), nor did the clinical risk fac-
tors affect the results when included in the logistic regres-
sion analyses. When the northern Finnish and Canadian
populations were combined, there were no significant as-
sociations with BPD (data not shown). There were no sta-
tistically significant haplotype associations with BPD in
the genes studied when the two populations were analyzed
separately or combined (data not shown).
Analysis of IL-6, TNF and gp130 proteins in cord blood
Cord blood IL-6, TNF and gp130 were higher in very pre-
term infants who subsequently developed BPD (n =35)
than in those who did not develop BPD (n =85) (median
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FU in cases vs. 347 FU in controls, P =0.002; 46,419 FU in
cases vs. 34,063 FU in controls, P <0.001, respectively).
Higher gp130 content predicted the risk of moderate-to-
severe BPD as reported previously [15]. There were no
statistically significant differences in the measures of cord
blood IL-6, TNF or gp130 among the genotypes of the
IL6, TNF or IL6ST SNPs, respectively. Small number of
cases or individuals with the minor alleles of the SNPs
may have limited the power for statistical significance.
Study of epistasis (SNP–SNP interactions)
Pairwise SNP–SNP interaction analyses were performed
to identify epistasis between genes located in different
genomic regions or chromosomes and to assess the
interactions for associations with BPD susceptibility. A
total of 231 valid SNP–SNP tests were performed with
the 22 SNPs included in the analyses (corrected P value
threshold <0.00022). In the northern Finnish population,
there was a SNP–SNP interaction that showed border-
line significance for risk of moderate-to-severe BPD; this
interaction was between IL6ST rs10471960 and IL10
rs3024493 SNPs (P =0.0003, ORinteraction =35.4; Table 4).
The homozygote carriers of major alleles of both SNPs
(i.e., carrying both AA and GG genotypes of IL6ST
rs10471960 and IL10 rs3024493, respectively) were at
higher risk of BPD. Furthermore, the cases tended to
have a higher combined major allele (A-G) frequency
compared to controls (83.8% vs. 75.3%, respectively).
Thus, a combination of the major alleles could increase
susceptibility to BPD or the minor alleles could be pro-
tective. This interaction between IL6ST rs10471960 and
IL10 rs3024493 SNPs was not detected in the Canadian
population (P =0.65) or when the populations were com-
bined (P =0.020). In addition, no statistically significant
interactions were detected in the Canadian population
(P >0.005) or in the combined northern Finnish and
Canadian populations (P >0.01).
Replication study of IL6ST rs10471960 and IL10 rs3024493
SNPs in BPD susceptibility
Due to the suggestive signal in the epistasis analysis in
the northern Finnish population, the IL6ST rs10471960
and IL10 rs3024493 SNPs were further analyzed in theTable 4 Results of epistasis analysis in the northern Finnish p
Chr 1 Gene 1 SNP 1 Chr 2
1 IL10 rs3024493 5
1 IL6R rs1386821 7
5 NR3CI rs17209237 6
1 IL10 rs3024493 5
*None of the interactions were significant after correcting for multiple comparisons
P values <0.01 are shown.replication population that included the additional Finnish
and Hungarian populations. In the single marker associ-
ation analysis, these two SNPs were not associated with
BPD in the replication Finnish or Hungarian populations,
or when the replication populations were combined with
the initial populations. In the epistasis analyses, the inter-
action between the two SNPs was not significant in the
replication Finnish (P =0.30) or Hungarian (P =0.61)
populations, or when the initial northern Finnish and
Canadian populations were combined with the replication
populations (P =0.13). The frequencies of the combined
major alleles remained similar to those observed in the
northern Finnish population (83.8% in cases vs. 75.3% in
controls), but the difference in the frequency between
cases and controls was smaller in the sample set that in-
cluded all of the studied populations (76.1% in cases vs.
73.8% in controls).
Discussion
Despite the remarkable advances in perinatal care, BPD
continues to be a major complication of prematurity. The
increased survival of extremely preterm infants has con-
tributed to an overall increase in the incidence of BPD
with a long-term risk of respiratory dysfunction [1,2]. BPD
occurs as the result of complex gene–environment inter-
actions, but the etiology of BPD remains incompletely
understood. Identification of the genetic component by
family studies has highlighted the importance of genetic
factors in predisposition to BPD [9]. Several polymor-
phisms have been associated with BPD in candidate gene
and genome-wide association studies, but the associations
have not been replicated at a statistically significant level
[8,10,11]. However, considering the high (~80%) herita-
bility of BPD, only a small part of this heritability can be
explained by the potential susceptibility SNPs discovered
thus far.
In the present case–control study, we investigated
whether the IL6, IL6R, IL6ST, IL10,TNF, and NR3C1 genes
were associated with susceptibility to BPD or whether the
genes have effect on cord blood serum protein levels at
the time of birth. These genes were selected based on their
involvement in inflammatory responses and lung matur-
ation. To our knowledge, no previous genetic studies of
BPD have reported significant associations between any ofopulation
Gene 2 SNP 2 P value of interaction*
IL6ST rs10471960 0.0003
IL6 rs2069832 0.0025
TNF rs1800629 0.0049
NR3C1 rs17209237 0.0063
(P <0.0002 as threshold for significance). Only SNP x SNP interactions with
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of TNF polymorphisms yielded inconsistent results or asso-
ciations that have not been replicated in subsequent studies
[31-33]. In addition to single-SNP analyses, we investigated
whether there is evidence for epistasis between these genes
in predisposition to BPD. None of the 44 polymorphisms
that we studied showed significant associations with BPD
in the single marker case–control analyses. There were
no significant associations between cord blood IL-6, TNF
and gp130 and polymorphisms of the encoding genes. In
the epistasis study, a suggestive interaction between IL6ST
rs10471960 and IL10 rs3024493 SNPs was observed in
the population that originated in the northern Finland
(P =0.0003). This interaction did not remain significant
for predisposition to moderate-to-severe BPD after cor-
rection for multiple comparisons, and the detected
interaction was not replicated in the additional studied
populations.
Epistasis may be one of the factors that account for
the missing heritability in complex diseases [34]. However,
assessing whether the detected interactions in epistasis
analyses represent true gene–gene interactions is not a
straightforward task. To our knowledge, interactions be-
tween IL6ST and IL10 have not been reported previously.
IL-6 levels and actions, namely, IL-6 signaling, are
dependent on the two receptors IL-6R and gp130. gp130,
encoded by IL6ST, is a common receptor subunit that is
shared with other receptors belonging to the IL-6 cytokine
family. Different pathways of IL-6 signaling represent dif-
ferent types of cells that respond to IL-6; this could ex-
plain both the pro- and anti-inflammatory actions of IL-6
cytokine [35,36]. In infants that subsequently developed
BPD, increased concentrations of IL-6 and soluble forms
of IL-6R and gp130 were observed with different ratios
in tracheal aspirate suggesting that altered IL-6 signaling
may have a role in pulmonary inflammation [37]. Add-
itionally, high cord blood levels of soluble gp130 at birth
have been shown to predict subsequent development
of BPD among very preterm infants [15], and the role of
IL-10 in BPD has been investigated [13,38]. Thus, the
potential interaction we observed in this study may be
biologically relevant, but it requires further investigation.
The strengths of our study are the use of genetically
relatively homogenous Finnish populations, the availabil-
ity of multiple populations of European descent (i.e. we
did not include individuals of clearly different ethnicities
to avoid bias arising from population structure), and
the strict phenotypic criteria among the participating
centers. We analyzed common polymorphisms of several
genes with potentially relevant roles in the pathogenesis
of BPD. Possible limitations of this study are that the ini-
tial study population (northern Finnish) was relatively
small and that the suggestive interaction was not ob-
served in the other populations. Our northern Finnishpopulation is likely more genetically homogenous than
populations that originated in other parts of Finland [39]
and compared to other populations of European origin
[40]. This could have affected the different patterns of
interaction between SNPs that we observed among the
different populations in this study. An additional replica-
tion study is needed, with a larger population.Conclusions
None of the polymorphisms within the IL6, IL6R, IL6ST,
IL10, TNF, and NR3C1 genes were associated with BPD
susceptibility, nor were they associated with the measured
biomarkers. We observed a modest evidence of epista-
sis, i.e., a potential SNP–SNP interaction that could be as-
sociated with the risk of BPD. To our knowledge, epistasis
has not been previously addressed in genetic studies of
BPD. We propose that further studies of gene–gene inter-
actions in the etiology of BPD are needed.Additional file
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